potential buy is regn in the red today
however big cap biotech is not going to move as fast as small cap biotech
i like small cap biotech stocks on the move better = jump in and out for fast cash
21.89 now off she flies even more at 2:30 p.m. = karumba green $$$
your play with rlyp is done ... move on to other(s) on the move ....
2:30 p.m. knocks at the door and i am gone with a pocket full of green cash ... ehhehehehhh
=== Relypsa, Inc. (RLYP) today announced that John A. Orwin, president and chief executive officer, will present at the Cantor Fitzgerald 2nd Annual Healthcare Conference on July 12, 2016 at 2:30 p.m. ET.
Good news and stock flies into green sky baby ...
=== Relypsa, Inc. (RLYP), a biopharmaceutical company, today announced that results of a pre-specified exploratory analysis of the Phase 3 OPAL-HK trial of Veltassa® (patiromer) for oral suspension were published online by Kidney International, the journal of the International Society of Nephrology. The previously published OPAL-HK study evaluated Veltassa in patients with hyperkalemia (elevated blood potassium levels) and chronic kidney disease (CKD) who were taking renin angiotensin aldosterone system (RAAS) inhibitors. Results of this newly published analysis found that patients taking Veltassa in the study had significant decreases in systolic and diastolic blood pressure and reduced levels of aldosterone in the blood. Aldosterone is a hormone that plays an important role in the body’s regulation of blood pressure and blood potassium levels.
“High aldosterone levels can be problematic for patients as they are associated with worsening of cardiovascular and kidney disease and are associated with increases in blood pressure,” said Matthew R. Weir, M.D., lead author of the Kidney International paper, lead investigator of the OPAL-HK trial, and professor and director of the Division of Nephrology at the University of Maryland School of Medicine in Baltimore. “This analysis suggests that patiromer’s potassium lowering effects may be associated with reductions in blood pressure and aldosterone production. These findings could be important for people with CKD and are worth evaluating further.”